What Is Petrelintide? The Amylin Drug Being Studied for Weight Loss

Petrelintide is an investigational weight-loss injection that works through amylin, a satiety hormone separate from the GLP-1 pathway, and its main selling point is tolerability: in trials it produced solid weight loss with side effects close to placebo. Developed by Zealand Pharma (now partnered with Roche), it’s a once-weekly shot and is not FDA approved. In a mid-stage trial it produced up to about 10.7% weight loss, notably with very few of the nausea-and-vomiting issues common to this drug class. Here’s what makes petrelintide stand out.

The Tolerability Story

The single most interesting thing about petrelintide is how gentle it appears to be. GLP-1 drugs are effective but often cause significant gastrointestinal side effects, especially early on, and those side effects are a major reason people stop treatment. Petrelintide’s trials have reported a strikingly clean profile. In its phase 2 study, at the most effective dose, there were reportedly no cases of vomiting and no discontinuations due to gastrointestinal side effects. For a drug producing double-digit weight loss, that’s an unusual combination.

This matters because obesity treatment is usually long-term. A drug people can actually stay on comfortably could, in practice, deliver better real-world results than a more powerful drug that many patients abandon due to side effects.

How Amylin Works

Petrelintide is a long-acting amylin analog. Amylin is a hormone your pancreas releases with insulin after meals, and it promotes fullness by acting directly on satiety centers in the brain and by restoring sensitivity to leptin (another fullness hormone). This is a different mechanism from GLP-1 drugs, which is part of why the side-effect profile differs.

Petrelintide was also engineered for stability, avoiding the clumping problems of natural amylin, which allows once-weekly dosing and even potential co-formulation with other drugs. It’s also designed to preserve lean muscle mass during weight loss, another selling point.

What the Research Shows

Early clinical data reported in the journal Diabetes, published by the American Diabetes Association in 2024, found that petrelintide was well tolerated and showed the potential to reduce body weight, with gastrointestinal tolerability improving when the dose was increased gradually. The larger phase 2 trial (ZUPREME-1) later reported up to about 10.7% average weight loss at 42 weeks versus roughly 1.7% on placebo, reinforcing both the efficacy and the favorable tolerability.

Where It’s Headed

Zealand and Roche have announced plans to advance petrelintide into phase 3 testing, both on its own and in combination with Roche’s dual GLP-1/GIP drug. Consider a hypothetical patient who tried a GLP-1 drug but quit within weeks because the nausea was unbearable. A well-tolerated amylin option could be exactly what makes treatment sustainable for them, which is the patient group petrelintide seems well suited to.

What This Means for You Right Now

Petrelintide is not available, and TrimRx does not offer it. TrimRx provides medications you can access today, including compounded semaglutide and compounded tirzepatide plus brand options like Ozempic, Wegovy, Mounjaro, and Zepbound. If you’re ready to pursue weight loss now, those available options are where to start, since petrelintide is still in development.

Petrelintide’s tolerability profile makes it one of the more promising candidates in the pipeline, but it remains a future prospect rather than a current treatment.

Frequently Asked Questions

What makes petrelintide different from GLP-1 drugs?

Petrelintide works through amylin rather than GLP-1, a different satiety pathway. The practical difference in trials has been tolerability: petrelintide produced double-digit weight loss with far fewer gastrointestinal side effects than GLP-1 drugs typically cause.

Is petrelintide FDA approved?

No. Petrelintide is investigational and not FDA approved. It has completed phase 2 testing and is heading into phase 3, so it’s only available through clinical trials.

Can I get petrelintide from TrimRx?

No. TrimRx offers currently available medications like compounded semaglutide and tirzepatide and brand GLP-1 options. Petrelintide is not approved or available and is not among them.

To focus on what you can actually start with today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. Petrelintide is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.